ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2154 entries already.
Special immune cells that protect the lining of the gut remain in a semi-active state, ready to fend off a pathogen at any moment, thanks to the composition of their mitochondrial membrane, a new study reveals.
A team of Austrian, Hungarian and Canadian researchers has demonstrated that Boehringer Ingelheim’s FDA-approved ERB family kinase blocker afatinib prolonged survival in hard-to-treat K-RAS-mutated lung tumours.
Swiss Novimmune SA has exclusively sold a licence option on its lead product NI-1701 (now renamed TG-1801), a bispecific anti-CD47/anti-CD19 antibody designed to trea B-cell blood cancers, to TG Therapeutics Inc.
For two days, innovation in synthetic and bio-based fine chemicals will be in the focus of experts who meet at Chemspec Europe in Cologne (20-21 June, 2018, Koelnmesse).
Three years ago Roche acquired a majority in shares of Foundation Medicines Inc (FMI), a specialist in cancer panel sequencing, which has build a huge database with cancer mutation profiles. Now Roche paid US2.4bn to complete the take-over.
Researchers at French antibiotics specialist Deinobiotics SAS, a subsidiary of Deinove SA, and German researchers announces the discovery of a new class of resistance breaking antibiotics that kill MRSA or S. pneumoniae effectively.
Following a letter of about 1,000 EPO patent examiners , also patent attorneys have send an open letter to the European Patent Office (EPO), criticising its outgoing president for having established work routines that are set to lower quality of European patents.
Adrenomed AG announced the publication of three scientific papers revealing how its adrenomedullin-targeting Phase II sepsis antibody Adrecizumab reverses vascular hyperpermeability in sepsis.
As first regulatory body in the world, the FDA has presented a market-driven reimbursement mechanism for antibiotics that may incentivise drug development in a niche market with currently low return on investment.
Celonic AG has pursued an ambitious expansion strategy in mammalian cell line contract manufacturing to establish Phase III and commercial supply by mid-2019. A new GMP facility in Heidelberg was acquired, and capacity is also being expanded at the headquarters in Basel. European Biotechnology spoke with Franzpeter Bracht, COO of Celonic, about Celonic’s strategy.